1. The mechanisms of pharmacokinetic food-drug interactions – a perspective from the UNGAP group;Koziolek;Eur. J. Pharmaceut. Sci.,2019
2. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol.,2010
3. Erlotinib, profiles drug subst;Abdelgalil;Excipients Relat. Methodol.,2020
4. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects;Frohna;J. Clin. Pharmacol.,2006
5. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer;Bakhtiary;Drug Dev. Ind. Pharm.,2017